• Advaxis Inc., of Princeton, N.J., raised $2 million by selling $2.3 million worth of convertible promissory notes. Each investor also received a warrant to acquire an additional half of a common share for each converted share. Rodman & Rensahw LLC acted as the exclusive placement agent. Proceeds will support Phase II trials of Advaxis' cancer immunotherapies.

• Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., is raising $3.5 million through a public offering of 3 million shares priced at $1.15 apiece, along with warrants to purchase an additional 1.5 million shares. The offering price represents an 11 percent discount to Catalyst's recent closing price. Net proceeds of $3.15 million will be used to support ongoing trials of treatments for drug addiction. Roth Capital Partners acted as sole manager for the offering.

• Spherix Inc., of Bethesda, Md., closed its previously announced $1.25 million private placement of stock and warrants. The firm sold 532,559 shares of common stock at $2.365 per share along with warrants to purchase an additional 532,559 shares of common stock at an exercise price of $2.24 per share. Rodman & Renshaw LLC acted as exclusive placement agent. Spherix plans to use proceeds to continue the development of SPX-106T (the combination of D tagatose and SPX-106). (See BioWorld Today, Oct. 8, 2010.)